1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Drugs In Development, 2022, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Corneal Neovascularization - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Corneal Neovascularization - Overview
- Corneal Neovascularization - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Corneal Neovascularization - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Corneal Neovascularization - Companies Involved in Therapeutics Development
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- FortuneRock (China) Ltd
- Gene Signal International SA
- Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd
- Kiora Pharmaceuticals Inc
- Singh Biotechnology LLC
- Wntgen LLC
- Corneal Neovascularization - Drug Profiles
- aganirsen - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Corneal Neovascularization - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate Raver-2 Protein for Ophthalmology Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Inhibit VEGF-A for Corneal Neovascularization - Drug Profile
- Product Description
- Mechanism Of Action
- JDE-006 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KDR-22 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KH-906 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Proteins for Oncology and Ophthalmology - Drug Profile
- Product Description
- Mechanism Of Action
- SBT-200 - Drug Profile
- Product Description
- Mechanism Of Action
- SFR-9X0122 - Drug Profile
- Product Description
- Mechanism Of Action
- Wnt-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Corneal Neovascularization - Dormant Projects
- Corneal Neovascularization - Product Development Milestones
- Featured News & Press Releases
- Jan 10, 2017: Zaphyr Pharmaceuticals and gene signal enter into collaboration for GS-101 (Aganirsen) in the Middle East & North Africa region
- May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation.
- Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure
- Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
- Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Corneal Neovascularization, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Corneal Neovascularization - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022
- Corneal Neovascularization - Pipeline by FortuneRock (China) Ltd, 2022
- Corneal Neovascularization - Pipeline by Gene Signal International SA, 2022
- Corneal Neovascularization - Pipeline by Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd, 2022
- Corneal Neovascularization - Pipeline by Kiora Pharmaceuticals Inc, 2022
- Corneal Neovascularization - Pipeline by Singh Biotechnology LLC, 2022
- Corneal Neovascularization - Pipeline by Wntgen LLC, 2022
- Corneal Neovascularization - Dormant Projects, 2022
- Number of Products under Development for Corneal Neovascularization, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- FortuneRock (China) Ltd
- Gene Signal International SA
- Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd
- Kiora Pharmaceuticals Inc
- Singh Biotechnology LLC
- Wntgen LLC
